Compare AU & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | TAK |
|---|---|---|
| Founded | 1944 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9B | 52.4B |
| IPO Year | 2023 | N/A |
| Metric | AU | TAK |
|---|---|---|
| Price | $83.40 | $16.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $119.00 | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 2.9M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.94% | 3.24% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.71 | $0.16 |
| Revenue Next Year | $2.89 | $1.22 |
| P/E Ratio | ★ $23.93 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.36 | $12.99 |
| 52 Week High | $129.14 | $18.90 |
| Indicator | AU | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 63.92 |
| Support Level | $79.43 | $15.88 |
| Resistance Level | $88.90 | $16.92 |
| Average True Range (ATR) | 3.13 | 0.21 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 31.94 | 91.99 |
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.